SPRINT-TB brings together several inter-institutional research groups that will work together towards achieving the programme’s vision. A/Prof Thomas Dick’s group (Department of Microbiology, National University of Singapore) will work on identifying novel drug targets in mycobacteria, while Prof. Alex Matter’s team (Experimental Therapeutics Centre, A*STAR, Singapore) will focus on drug discovery, pre-clinical development and animal models. Programme’s clinical development theme, led by Prof. Nick Paton, will undertake TB drug clinical trials, including TRUNCATE-TB – a large phase 2/3 Asian multicentre trial for novel drug regimens in patients with drug-sensitive TB. Prof. Richard Coker (Saw Swee Hock School of Public Health, National University of Singapore) will lead treatment delivery research.
SPRINT-TB has also attracted numerous collaborators across Singapore's research institutions, Asian regional universities and hospitals, as well as academic and industry researchers in Europe and USA. The programme will be overseen by a Scientific Advisory Board comprising of invited independent experts.